Format

Send to

Choose Destination
Neuromuscul Disord. 2015 Jan;25(1):5-13. doi: 10.1016/j.nmd.2014.11.011. Epub 2014 Nov 24.

European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.

Author information

1
European Medicines Agency, London, United Kingdom. Electronic address: manuel.haas@ema.europa.eu.
2
European Medicines Agency, London, United Kingdom.
3
Läkemedelsverket, Medical Products Agency, Uppsala, Sweden.
4
Hôpital Maison Blanche, CHU de Reims, Reims, France.
5
Medicines and Healthcare Products Regulatory Agency, London, United Kingdom.
6
Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.
7
Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.
8
Medicines Evaluation Board, Utrecht, The Netherlands.
PMID:
25497400
DOI:
10.1016/j.nmd.2014.11.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center